SYMPLIFY, a prospective observational study, is the first large-scale evaluation of a multi-cancer early detection (MCED) test in individuals who presented with symptoms to primar ...

In a city, coworking hubs bring people and ideas together. Inside cancer cells, similar hubs form—but instead of fueling ...

GRAIL believes its cash, cash equivalents and investments, including the expected net proceeds from the private placement, will provide sufficient funding of planned operations into 2030, not ...

US-based company is developing next-generation sequencers, using AI models in the Republic to speed up diagnostics and lower ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Aurelius Omlin discussing optimized use of immunotherapy and targeted ...

After surviving three types of cancer and having to face the harsh realities of colorectal and endometrial cancer and basal ...

An MCED blood test increased screenable cancer detection more than 7-fold when added to the US Preventive Services Task Force (USPSTF) A/B recommended screening.

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength ...